<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04002830</url>
  </required_header>
  <id_info>
    <org_study_id>WI224302</org_study_id>
    <nct_id>NCT04002830</nct_id>
  </id_info>
  <brief_title>A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease</brief_title>
  <official_title>A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ari Zimran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter study to assess the safety and efficacy of taliglucerase alfa (60&#xD;
      units/kg) in previously untreated subjects of any age with Type 3 GD. Subjects will receive&#xD;
      an infusion of taliglucerase alfa every 2 weeks for 12 months. Subjects who tolerate the&#xD;
      infusions well, and who are treated in centers where home therapy is the SOC will be allowed&#xD;
      to switch from site to home treatment at the discretion of the PI but after no less than 3&#xD;
      uneventful infusions at the site.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Type 3 GD exhibit both visceral and neurologic manifestations. In addition to&#xD;
      the progressive neurologic involvement, somatic disease manifestations, especially&#xD;
      splenomegaly and resulting cytopenia, contribute to significant mortality and morbidity . The&#xD;
      effects of enzyme replacement therapy (ERT) on patients with Type 1 GD have been clearly&#xD;
      documented and have a beneficial effect on visceral and hematologic disease parameters . It&#xD;
      is known that recombinant enzyme does not pass the blood-brain barrier and has no effect on&#xD;
      neurologic involvement . Probably due to the rarity of Type 3 GD, information on the somatic&#xD;
      effects of ERT is largely limited to case reports or single-center series. There are also few&#xD;
      reviews of cohorts but the clinical subtype, age, genotype, ERT dosage, accompanying&#xD;
      therapies, and treatment response vary widely among patients in these cohorts. This&#xD;
      prospective study aims to objectively evaluate the hematologic and visceral effects of ERT&#xD;
      with taliglucerase alfa on a rather clinically and genetically homogenous group of&#xD;
      treatment-naïve patients with Type 3 GD . For the purposes of this study, subjects receiving&#xD;
      no Gaucher-specific medications for at least 12 months will be considered &quot;untreated&quot;. The&#xD;
      results of this study are expected to provide a more objective view of the degree of response&#xD;
      of this patient type, and potentially create new areas of research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Type 3 Gaucher disease patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in spleen volume measured by MRI</measure>
    <time_frame>from baseline to month 12</time_frame>
    <description>Percent change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in liver volume measured by MRI</measure>
    <time_frame>from baseline to month 12</time_frame>
    <description>Percent change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in hemoglobin</measure>
    <time_frame>from baseline to Months 3, 6, 9, and 12</time_frame>
    <description>Percent change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in platelet count</measure>
    <time_frame>from baseline to Months 3, 6, 9, and 12</time_frame>
    <description>Percent change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Lyso-GB1</measure>
    <time_frame>from baseline to Months 3, 6, 9, and 12</time_frame>
    <description>Percent change from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Gaucher Disease, Type 3</condition>
  <arm_group>
    <arm_group_label>Taliglucerase Alpha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of Taligluucerase alfa (Elelyso) in treatment-naive patients with type 3 Gaucher disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elelyso</intervention_name>
    <description>Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.</description>
    <arm_group_label>Taliglucerase Alpha</arm_group_label>
    <other_name>Taliglucerase Alfa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female of any age; however, if female:&#xD;
&#xD;
               -  must be using contraception if of childbearing potential or must be surgically&#xD;
                  sterile&#xD;
&#xD;
               -  must not be lactating&#xD;
&#xD;
          2. Diagnosis of Type 3 GD by enzyme and sequence analysis; and confirmed by the Medical&#xD;
             Monitor.&#xD;
&#xD;
          3. Splenomegaly at least 5 x multiples of normal (MN).&#xD;
&#xD;
          4. Treatment-naïve.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Eligible subjects may not have any of the following exclusion criteria:&#xD;
&#xD;
          1. Type 2 GD.&#xD;
&#xD;
          2. Presence of myoclonic seizures.&#xD;
&#xD;
          3. At least one allele of:&#xD;
&#xD;
               -  N370S (N409S in recent nomenclature)&#xD;
&#xD;
               -  R496H (R535H in recent nomenclature)&#xD;
&#xD;
          4. Presence of calcification in heart valves or arteries in echocardiography.&#xD;
&#xD;
          5. Presence of untreated iron, folic acid, vitamin B12 deficiency and/or hypothyroidism.&#xD;
             (Resolved anemia is not an exclusion criterion.)&#xD;
&#xD;
          6. Presence of human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg),&#xD;
             and/or hepatitis C infections.&#xD;
&#xD;
          7. Splenectomy and bone marrow transplantation.&#xD;
&#xD;
          8. Presence of any medical, emotional, behavioural, or psychological condition that in&#xD;
             the judgment of the Investigator would interfere with the subject's compliance with&#xD;
             the requirements of the study.&#xD;
&#xD;
          9. Any other disorder that may interfere with the results of the efficacy endpoints.&#xD;
&#xD;
         10. Pregnancy or breastfeeding.&#xD;
&#xD;
         11. Currently taking another investigational drug for any condition or any therapeutic&#xD;
             drug for Gaucher disease.&#xD;
&#xD;
         12. The subject and/or subject's parent(s) or legal guardian(s) are unable to understand&#xD;
             the nature, scope, and possible consequences of the study.&#xD;
&#xD;
         13. Medical history of any food/drugs allergy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ari Zimran, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Majdoleen J Istaiti, B.Sc</last_name>
    <phone>+972-52-6659995</phone>
    <email>joleenist@szmc.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhulika Kabra, M.D</last_name>
      <email>madhulikakabra@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Majdolen J Istaiti, B.Sc</last_name>
      <phone>+97-52-6659995</phone>
      <email>joleenist@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Ari Zimran, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shoshana Revel-Vilk, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gazi University</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fatih Ezgu</last_name>
      <email>fatih.ezgu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
    <country>Israel</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shaare Zedek Medical Center</investigator_affiliation>
    <investigator_full_name>Ari Zimran</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

